

Review Article

The Impact of COVID-19 Pandemic on Arthropod-Related Diseases

*Vahideh Moin-Vaziri¹, Mehdi Badakhshan²

¹Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Medical Entomology and Vector Control, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran

*Corresponding author: Dr Vahideh Moin-Vaziri, E-mail: vmvaziri@gmail.com, v.vaziri@sbmu.ac.ir

(Received 11 July 2021; accepted 12 Mar 2023)

Abstract

Background: The Covid-19 pandemic that caused by the infection with the novel Coronavirus SARS-CoV-2 has revealed individual and global vulnerabilities all over the world. Many countries that had been struggled with arthropod-borne diseases (VBDs) are now embroiled in another challenge caused by COVID-19 pandemic. The situation that poses major obstacles 1) by misdiagnosis 2) delay in early and appropriate treatment of VBDs 3) difficulties in applying regular strategy for vector control and prevention methods and finally 4) irregularity in financing supports. Given the possible scenario of syndemics, it is important to plan integrated and combined measurement with the maximum participation of the people and health authorities. Here, the impact of COVID-19 pandemic on some major arthropod-related diseases will be discussed.

Methods: To access the collective data all related databases such as Science direct, PubMed, Elsevier, Google scholar, as well WHO web page were searched with key words “arthropoda-related diseases, COVID-19 with the name of each individual disease”.

Results: The results showed that the management, control, and treatment of most important arthropod-related diseases could be delayed due to COVID-19 pandemic.

Conclusion: Dealing with COVID-19, it is crucial to consider the other main killers such as malaria, dengue fever, etc. more especially in vulnerable populations by greater political, financial and global commitment. Continued surveillance will be essential to monitor for any possible changes.

Keywords: Arthropoda-related diseases; COVID-19; Syndemics

Introduction

Arthropods are large phylum in the kingdom Animalia and include most known animal species mainly belong to insects, spiders, mites, ticks, and scorpions. They may effect on human health by direct effects, such as bites/stings, allergic reactions, entomophobia, myiasis or indirectly by the transmission of some important diseases like malaria, leishmaniasis, dengue fever, yellow fever, and so on (1-2). They caused a lot of morbidity, mortality and economic losses, globally (2).

To make a brief reference to the importance of vector borne diseases (VBDs), it is suffice

to look at the global statistics; malaria global cases in 2020 was reported as 241 million cases, and the estimated number of malaria deaths stood at 627000 (3). Annual new cases of leishmaniasis estimated as 700000 to 1 million, out of them 50000 to 90000 cases belong to the visceral leishmaniasis, fatal form of disease (4). The number of dengue cases increased dramatically about eight fold over the last two decades and has been listed as a potential threat for 2020 and recent outbreaks in many countries confirmed this claim, with 100–400 million infections annually (5). Although

these data help us to have a glimpse on the importance of VBDs, but this is not the whole story, just a handful of examples.

Several factors could affect on VBDs such as climate change, trade and travel (esp. global air travel and seaborne trade), human migration, socio-economic and ecological drivers (land use, farming practices, natural fauna, public health situation, human life style...), and as well political agenda. Any other factor that changed these elements will affect the prevalence and incidence of VBDs. Recently, the COVID-19 pandemic has led to significant loss of life and impact on other aspects of human life such as public health, food systems and the world of work, resulting in extreme poverty and poor public health (6-7). The purpose of this article is to emphasize on the impact of COVID-19 on the most important arthropod problems based on available literatures.

COVID-19 and Malaria

Malaria caused by different species of *Plasmodium* and transmitted by anopheline mosquitoes, it is one of the highest contributors to morbidity and mortality in the world, with 627000 death in 2021 (3). The declining malaria burden over the past 20 years reflects major advances in disease control due to multidisciplinary interventions in the vector control, early diagnosis and anti-malarial therapies (8). This trend creates a promising outlook to eliminate malaria from Asia pacific by 2030 and Africa by 2050, a success which seems fragile and probably remains behind due to COVID-19. As a prediction, the world will return to the level of mortality in 2000 (7, 9-10). Also, it was stated that deaths due to malaria could increase over 5 years up to 36%, compared with no COVID-19 pandemic (11). One of the risk factors for malaria expansion is travelling to/or from endemic areas (12) at first glance, travel restrictions due to the COVID-19 quarantines could be regarded as a positive hint, but will be faded by some adverse impact of COVID-19 on; 1) malaria

vector control (irregularities in insecticide-treated nets distribution as well, larval and adult mosquito control measurements), 2) detection and treatment (interruption the health facilities due to the fear of exposure to COVID-19, difficulty in transportation, need of additional resources to protect health care workers from COVID-19, 3) economic collapse and health system failure, 4) population movement due to the economic crisis (11–. Malaria control can be affected by other potential factors, such as the death of health care workers, as well by misdiagnosis of malaria cases in returning travelers in time of COVID-19 pandemic (11, 13–14), 16-17). Practical recommendations for decision maker are available to keep the staff safe and to maintain main services at community level (18). Continued and more concentrated epidemiological surveillance will be essential to better withstand challenges in malaria endemic area (19).

COVID-19 and Leishmaniasis

Leishmania is an obligate intracellular pathogen that invades phagocytic host cells, and it was transmitted to vertebrate hosts by approximately 30 species of phlebotomine sand flies. Leishmaniasis is among the neglected tropical disease (NTDs), with three main clinical forms, visceral (the most serious form), cutaneous (the most common), and mucocutaneous. Globally, about 90 countries are considered endemic for leishmaniasis (20) so it is very likely that leishmaniasis and COVID-19 have a spatial and temporal overlaps. Leishmaniasis is associated with poverty, lack of basic sanitation, malnutrition, population displacement, poor housing, weak immune system and lack of financial resources (4). As COVID-19 triggered the individual and global vulnerabilities, it is well clear that it could have an enhancing effect on leishmaniasis burden as reported from Brazil recently (21). In the fear of corona virus patients who were suspected to cutaneous form of disease may not refer to the physician in appropriate time that not only exacerbate the lesions but also effect on the transmission

cycle of disease, especially in the anthroponotic form which humans act as main reservoirs. On notice, in visceral form, as the fatal form of leishmaniasis, the situation is more complicated. Although it does not share clinical features with COVID-19, but because of distinct immunopathogenesis between diseases, VL patients showed vulnerability in their immune system against antiviral responses (22-23) So, endemic neglected diseases like VL should be more considered during COVID-19 pandemic.

COVID-19 and arthropod-borne viruses

The term “arboviruses” refers to the viruses that biologically transmitted to vertebrates by different species of arthropods mainly culicine mosquitoes and ixodid ticks (24). It is important to raise the global awareness on the possible impact of COVID-19 on arboviral diseases. The most important arboviruses will be discussed following.

COVID-19 and Dengue fever

Dengue is a major public health problem especially in tropical and sub-tropical regions; it is caused by four serotypes of dengue virus (DENV) and transmitted by mosquitos, mainly by *Aedes aegypti*. The global incidence of dengue has grown dramatically recently and about half of the world's population is now at risk. The number of dengue cases increased 8 fold over the last two decades, from 505,430 cases in 2000, to over 4.2 million in 2019. Reported death cases between the year 2000 and 2015 increased from 960 to 4032 (5). In syndemic areas of dengue fever and COVID-19 the problem increased for the health system(25-26). Similar clinical manifestations shared by COVID-19 and dengue fever have raised concerns in two ways; at first by confusing the physicians in the correct diagnosis of disease, considering this fact that dengue is the leading cause of febrile illnesses in travelers who returns from South-East Asia (25-27), secondly by potential false-positive results in the patients with pre-existing DENV antibodies that

could make a cross-reactivity between SARS-CoV-2 and DENV. Although, the results of a preliminary study in Italy on a small number of serum samples (32 samples) can downsize this concern as they stated that “the concern about false-positive dengue serology in COVID-19 patients could be downsized, at least when an ELISA is used” (28).

By the way, in endemic areas of dengue, COVID-19 act as a double punch for patients and for public health by further spread of the virus and the risk of health-workers collapsing (26, 29-35).

On the other hand, in the lack of vaccine and specific treatment for dengue fever, the only intervention method that seems to work is vector control, (5) which accordingly might have decreased in the community and dengue prevention programs during COVID-19 pandemic (36-37). Since simultaneous infections will worsen the epidemiological situation, special attention should be done on the patients who live or had the history of travel to dengue endemic areas. It should be mentioned that the restriction on movement of people to curb Covid-19 could decrease the cases in a period of time as reported in Sri Lanka (38).

COVID-19 and Yellow fever

Yellow fever which mostly occurs in South America and Sub-Saharan Africa, is an acute viral hemorrhagic disease caused by a mosquito-borne flaviviruses. The "yellow" in the name refers to the jaundice that affects some patients. Yellow fever control started by early application of quarantine in 15th century and shifted to more coordinated approach through time, and today includes vaccine requirement at the entrance of the countries (39). There is currently no specific antiviral drug for yellow fever, but the Eliminate Yellow fever Epidemics Strategy (EYEs) that launched in 2017, aimed to protected more than 1 billion people by 2026 (40). Large-scale vaccination is the main arm of this struggle, and unfortunately easily could affected by COVID-19 pandem-

ic, especially in Syndemic areas (41-42). Although some restriction rules for COVID-19, such as home quarantine, closing the borders, travel restriction and prohibition of social and religious events could mitigate yellow fever dispersion too, but the adverse effects of the current pandemic cannot be ignored. Without a doubt, the main obstacle is the economic crisis of the countries that affect the health system and the routine diplomacy. Regularly, risk of yellow fever in urban areas could be reduced by eliminating the potential mosquito breeding sites by applying larvicides in water storage containers and anywhere that standing water collect (40), which under the shadow of COVID-19 will certainly be affected (43).

COVID-19 and Zika virus

Zika virus is a *Flavivirus* that firstly identified in 1947 in monkeys, the initial report of humans infection was in Uganda and the United Republic of Tanzania in 1952 which continued by several epidemics in different countries in 2007, 2013 and 2015 (large outbreak in Brazil). The main vector is day-biting mosquito *Aedes aegypti* (44). So far, no vaccines or antiviral drugs are licensed for ZIKA, so the only way left is 1) personal protection against mosquito bites during the day and early evening 2) using physical barriers 3) applying insect repellent to skin or clothing and finally 4) elimination mosquito breeding sites. The latter one requires community initiatives to support local government and public health programs to reduce mosquito breeding sites (44), which will certainly be affected by the problems caused by the COVID-19 (45).

COVID-19 and Pediculus

Human Pediculus is defined as infestation to body lice (*Pediculus humanus*) and head lice (*Pediculus capitis*). Pediculus due to head lice still remains a public health problem, it is extremely contagious, it could be found in any age, but it is more common among young children aged 3 to 12 years (46). Transmission

had occurred commonly by close human-to-human contact, through social and family relationships(46). Two main strategies against pediculosis are individual control and prevention of its transmission (46). When WHO declared the COVID-19 as a global pandemic in March 2020, the governments of different countries imposed the mandatory quarantine, social distance, and public lock down. These restriction rules forced the students, as the most vulnerable ones for pediculosis, to stay at home and have virtual education; as a result the close contact was interrupted and it can be concluded that it will have a reducing effect on the prevalence of *P. capitis*, the fact that was proved by a survey in Argentina (46).

COVID-19 and scabies

Scabies is one of the earliest human diseases caused by *Sarcoptes scabiei* and transmitted by direct skin-to-skin contact (47). Regardless of socioeconomic status, it is a public health issue in all countries, but its prevalence would be enhanced with poverty, malnutrition, overcrowded conditions, and immune-compromised status (48-49). Delay in refereeing to the physician can lead to delay in diagnosis and inadequate treatment which in turn can lead to further dispersion; a condition that occurs more frequently during COVID-19 quarantine in comparison to the life before (50-51).

Conclusions

Dealing with COVID-19, it is crucial to not ignore the other main killers such as malaria, dengue fever and so forth. More especially in vulnerable populations by greater political, financial, and global commitment.

Acknowledgments

We would like to thank all scientists who have worked on this matter for ages whose work is pointed out here.

Conflict of interest statement

The authors declare there is no conflict of interests.

References

- Goddard J (1999) Arthropods and medicine. *J Agromedicine*. 5(4): 55–82.
- Pollack RJ, Marcus LC (2005) A travel medicine guide to arthropods of medical importance. *Infect Dis Clin*. 19(1):169–83.
- WHO (2022) Malaria. World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/news-room/fact-sheets/detail/malaria>.
- WHO (20 May 2021) Leishmaniasis. World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/news-room/fact-sheets/detail/leishmaniasis>.
- WHO (2022) Dengue fever. World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>, 2022
- Semenza JC, Suk JE (2018) Vector-borne diseases and climate change: a European perspective. *FEMS Microbiol Lett*. 365 (2): fnx244.
- WHO (2020) Impact of COVID-19 on people's livelihoods, their health and our food systems. World Health Organization; Available at: <https://www.who.int/news/item/13-10-2020-impact-of-covid-19-on-people's-livelihoods-their-health-and-our-food-systems>.
- WHO (2021) Malaria. World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/news-room/fact-sheets/detail/malaria>.
- WHO (2021) Global Technical Strategy for Malaria 2016–2030. World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/news-room/fact-sheets/detail/malaria>.
- Chioldini J (2020) COVID-19 and the impact on malaria. *Travel Med Infect Dis*. 35: 101758.
- Hogan AB JB, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, Hamlet A, Smith JA, Winskill P, Verity R, Baguelin M, Lees JA, Whittles LK, Ainslie KEC, Bhatt S, Boonyasiri A, Brazeau NF, Cattarino L, Cooper LV, Coupland H, Cuomo-Dannenburg G, Dighe A, Djaafara BA, Donnelly CA, Eaton JW, van Elsland SL, FitzJohn RG, Fu H, Gaythorpe KAM, Green W, Haw DJ, Hayes S, Hinsley W, Imai N, Laydon DJ, Mangal TD, Mellan TA, Mishra S, Nedjati-Gilani G, Parag KV, Thompson HA, Unwin HJT, Vollmer MAC, Walters CE, Wang H, Wang Y, Xi X, Ferguson NM, Okell LC, Churcher TS, Arinaminpathy N, Ghani AC, Walker PGT, Hallett TB (2021) Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. *Lancet Glob Health*. 8(9): e1132–e1141.
- WHO (2020) coronavirus disease (COVID-19) pandemic. World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
- Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, Price RN (2020) Identifying and combating the impacts of COVID-19 on malaria. *BMC medicine*. 18(1): 1–7.
- Hussein MIH, Albashir AAD, Elawad OAMA, Homeida A (2020) Malaria and COVID-19: unmasking their ties. *Malar J*. 19(1):1–10.
- Hakizimana D NC, Mbituyumuremyi A, Hakizimana E, Mahmoud H, Birindabagabo P, Musanabaganwa C, Gashumba D (2022) The impact of Covid-19 on malaria services in three high endemic

- districts in Rwanda: a mixed-method study. *Malar J.* 21(1): 48.
16. Gutman JR, Lucchi NW, Cantey PT, Steinhart LC, Samuels AM, Kamb ML, Kapella BK, McElroy PD, Udhayakumar V, Lindblade KA (2020) Malaria and parasitic neglected tropical diseases: potential syndemics with COVID-19? *Am J Trop Med Hyg.* 103(2): 572–577.
 17. Lev D, Biber A, Lachish T, Leshem E, Schwartz E (2020) Malaria in travellers in the time of corona. *J Travel Med.* 27(6): 1–2.
 18. WHO (2022) World Health Organization, Geneva, Switzerland. Available at: <https://www.who.int/publications-detail/community-based-health-care-including-outreach-and-campaigns-in-the-context-of-the-covid-19-pandemic>.
 19. Mohanan P IZ, Hasan MM, Adedeji OJ, Dos Santos Costa AC, Aborode AT, Ahmad S, Essar MY (2022) Malaria and COVID-19: A double battle for Burundi. *Afr J Emerg Med.* 12(1): 27–29.
 20. WHO (2019) Leishmaniasis. World Health Organization, Geneva, Switzerland. Available at: https://www.who.int/health-topics/leishmaniasis#tab=tab_1.
 21. Andrade MC FBP, Hilan E, Marques NP, Guimarães-Carvalho SF, Martelli H Junior (2021) COVID-19 Pandemic Causes Increased Clinic Visits with Diagnosis of Tegumentary Leishmaniasis in Brazil in 2020. *Int J Infect Dis.* 113: 87–9.
 22. Carvalho SFG, Vieira TM, Moura APV, Andrade MC (2020) Should an intersection between visceral leishmaniasis endemicity and the COVID-19 pandemic be considered? *Med Hypotheses.* 144: 110289.
 23. Pikoulas A PE, Spanakos G, Kallianos A, Mparmparousi D, Rentziou G, Trakada G (2022) Visceral leishmaniasis and COVID-19 coinfection - A case report. *IDCases.* 27: e01358.
 24. WHO (1967) Arboviruses and human disease. World Health Organization; Available at: https://apps.who.int/iris/bitstream/handle/10665/40664/WHO_TRS_369.pdf?sequence=1&isAllowed=y.
 25. Joob B, Wiwanitkit V (2020) COVID-19 can present with a rash and be mistaken for dengue. *J Am Acad Dermatol.* 82(5): e177.
 26. Lorenz C, Azevedo TS, Chiaravalloti-Neto F (2020) COVID-19 and dengue fever: A dangerous combination for the health system in Brazil. *Trop Med Infect Dis.* 35: 101659.
 27. Mascarenhas MDM, Batista FMdA, Rodrigues MTP, Barbosa OdAA, Barros VC (2020) Simultaneous occurrence of COVID-19 and dengue: what do the data show? *Cad Saude Publica.* 36: e00126520.
 28. Spinicci M, Bartoloni A, Mantella A, Zammarchi L, Rossolini GM, Antonelli A (2020) Low risk of serological cross-reactivity between dengue and COVID-19. *Mem Inst Oswaldo Cruz.* 115: 1–4.
 29. Yan G, Lee CK, Lam LT, Yan B, Chua YX, Lim AY, Phang KF, Kew GS, Teng H, Ngai CH (2020) Covert COVID-19 and false-positive dengue serology in Singapore. *Lancet Infect Dis.* 20(5): 536–536.
 30. Saavedra-Velasco M, Chiara-Chilet C, Pichardo-Rodriguez R, Grandez-Urbina A, Inga-Berrosipi F (2020) Coinfection between dengue and covid-19: need for approach in endemic zones. *Rev Fac Cien Med Univ Nac Cordoba.* 77(1): 52–54.
 31. Ridwan R (2020) COVID-19 and dengue: a deadly duo. *Trop Doct.* 50(3): 270–272.
 32. Navarro J-C, Arrivillaga-Henríquez J, Salazar-Loor J, Rodriguez-Morales AJ (2020) COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: pushing strained health care systems over the edge. *Travel Med Infect Dis.* 37: 101656.

33. Cardona-Ospina JA, Arteaga-Livias K, Villamil-Gómez WE, Pérez-Díaz CE, Katterine Bonilla-Aldana D, Mondragon-Cardona Á, Solarte-Portilla M, Martinez E, Millan-Oñate J, López-Medina E (2021) Dengue and COVID-19, overlapping epidemics? An analysis from Colombia. *J Med Virol.* 93(1): 522–527.
34. Ulrich H, Pillat MM, Tárnok A (2020) Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. *Cytometry Part A.* 97(7): 662–667.
35. Wu D, Lu J, Liu Q, Ma X, He W (2020) To alert coinfection of COVID-19 and dengue virus in developing countries in the dengue-endemic area. *Infect Control Hosp Epidemiol.* 41(12): 1482.
36. Harapan H, Ryan M, Yohan B, Abidin RS, Nainu F, Rakib A, Jahan I, Emran TB, Ullah I, Panta K (2021) Covid-19 and dengue: Double punches for dengue-endemic countries in Asia. *Rev Med Virol.* 31(2): e2161.
37. Cruz J, Tovilla-Zárate CA, González-Morales DL, González-Castro TB (2020) Risk of a syndemic between COVID-19 and dengue fever in southern Mexico. *Gac Med Mex.* 156(5): 460–464.
38. Surendran SN NR, Sivabalakrishnan K, Arthiyan S, Tharsan A, Jayadas TTP, Raveendran S, Kumanan T, Ramasamy R (2022) Reduced dengue incidence during the COVID-19 movement restrictions in Sri Lanka from March 2020 to April 2021. *BMC Public Health.* 22(1): 1–10.
39. Vanderslott S MT (2020) Health diplomacy across borders: the case of yellow fever and COVID-19. *J Travel Med.* 27(5): 1–3.
40. WHO (2019) Yellow fever. World Health Organization, Geneva, Switzerland. [updated 7 May 2019]; Available at: <https://www.who.int/news-room/factsheets/detail/yellow-fever>.
41. Vasconcelos PFdC, Alcantara LCJ, Araujo WNd (2020) The obscurance of the greatest sylvatic yellow fever epidemic and the cooperation of the Pan American Health Organization during the COVID-19 pandemic. *Rev Soc Bras Med Trop.* 53: 1–5.
42. Gaythorpe KA AK, Huber J, Karachaliou A, Thakkar N, Woodruff K, Li X, Echeverria-Londono S; VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease, Ferrari M, Jackson ML, McCarthy K, Perkins TA, Trotter C, Jit M (2021) Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. *Elife.* 10: e67023.
43. Dantés HG, Manrique-Saide P, Vazquez-Prokopec G, Morales FC, Siqueira Junior JB, Pimenta F, Coelho G, Bezerra H (2020) Prevention and control of Aedes transmitted infections in the post-pandemic scenario of COVID-19: challenges and opportunities for the region of the Americas. *Mem Inst Oswaldo Cruz.* 115: 1–5.
44. WHO (2018) Zika virus. World Health Organization, Geneva, Switzerland. [cited 2018 20 July 2018]; Available at: <https://www.who.int/en/news-room/factsheets/detail/zika-virus>
45. Pannu J BM (2021) Global health security as it pertains to Zika, Ebola, and COVID-19. *Curr Opin Infect Dis.* 34(5): 401–408.
46. Galassi F O-II, Adjemian V, Gonzalez-Audino P, Picollo MI, Toloza AC (2021) Head lice were also affected by COVID-19: a decrease on Pediculosis infestation during lockdown in Buenos Aires. *Parasitol Res.* 120(2): 443–450.
47. Arlian LG, Morgan MS (2017) A review of *Sarcoptes scabiei*: past, present and future. *Parasit Vectors.* 10(1): 1–22.
48. Thomas C, Coates SJ, Engelman D, Chosidow O, Chang AY (2020) Ectopar-

- asites: scabies. *J Am Acad Dermatol.* 82 (3): 533–548.
49. Dubray CL, Sircar AD, de Rochars VMB, Bogus J, Direny AN, Ernest JR, Fayette CR, Goss CW, Hast M, O'brian K (2020) Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. *PLoS Negl Trop Dis.* 14(6): e0008298.
50. Pigliacelli F, Donà MG, Giglio A, Cameli N, Morrone A, Zaccarelli M, Latini A (2020) Did the coronavirus pandemic reveal old neglected infections? *Int J Dermatol.* 59(11): 1391–1392.
51. Kutlu Ö, Güneş R, Coerd K, Metin A, Khachemoune A (2020) The effect of the “stay-at-home” policy on requests for dermatology outpatient clinic visits after the COVID-19 outbreak. *Dermatol Ther.* 33(4): e13581.